Gyre Therapeutics, Inc. GYRE Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre Pharmaceuticals | $22.52M-39.5% | $37.2M+21.7% | $30.56M+14.2% | $26.77M+21.4% | $22.06M-20.9% | |
| Gyre | $0— | —— | —— | —— | $0— | |
| Other Nonoperating Income Expense by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0-100% | |
| Gyre | $191K+149% | -$387K-278% | $217K+136% | $92K+104% | $45K+123% | |
| Gyre Pharmaceuticals | -$162K+91.0% | -$1.81M-454% | $510K+315% | -$237K-482% | $62K+104% | |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest by Business | ||||||
| All Other Segments | -$6K-100% | -$3K+72.7% | -$11K-450% | -$2K+33.3% | -$3K— | |
| Gyre | -$6M-136% | -$2.54M-46.1% | -$1.74M+0.9% | -$1.75M-309% | $838K— | |
| Gyre Pharmaceuticals | -$3.85M-427% | $1.18M-84.7% | $7.69M+131% | $3.33M+14.9% | $2.9M+51.3% | |
| Operating Income by Business | ||||||
| All Other Segments | -$6K-100% | -$3K+72.7% | -$11K-450% | -$2K+33.3% | -$3K— | |
| Gyre | -$6.28M-107% | -$3.04M-57.3% | -$1.93M+6.2% | -$2.06M-40.8% | -$1.46M+7.2% | |
| Gyre Pharmaceuticals | -$3.07M-197% | $3.16M-64.4% | $8.87M+110% | $4.23M+13.2% | $3.74M+67.2% | |
| Operating Expenses by Business | ||||||
| All Other Segments | $6K+100% | $3K-72.7% | $11K+450% | $2K-33.3% | $3K— | |
| Gyre | $6.28M+107% | $3.04M+57.3% | $1.93M-6.2% | $2.06M+40.8% | $1.46M-7.2% | |
| Gyre Pharmaceuticals | $25.59M-32.2% | $37.71M+87.9% | $20.07M-6.2% | $21.39M+16.8% | $18.32M-35.4% | |
| Income Tax Expense Benefit by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre | $0— | —— | $2K— | —— | $0-100% | |
| Gyre Pharmaceuticals | $621K-52.2% | $1.3M-23.1% | $1.69M+155% | $662K-26.5% | $901K+348% | |
| Cost of Goods Sold by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre | $0— | —— | —— | —— | $0— | |
| Gyre Pharmaceuticals | $1.23M-29.6% | $1.74M+7.1% | $1.63M+41.4% | $1.15M+28.7% | $894K-24.0% | |
| Total Assets by Business | ||||||
| All Other Segments | $357K+0.3% | $356K-0.3% | $357K-2.2% | $365K0.0% | $365K-0.8% | |
| Gyre | $24.31M-11.2% | $27.37M-5.6% | $29M-6.9% | $31.14M+340% | $7.07M-34.4% | |
| Gyre Pharmaceuticals | $137.35M-0.8% | $138.41M+6.4% | $130.03M+7.3% | $121.14M-1.0% | $122.35M+7.1% | |
| Transaction Costs by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | —— | |
| Gyre Pharmaceuticals | $0— | —— | —— | —— | —— | |
| Gyre | $2.55M— | —— | —— | —— | —— | |
| Selling And Marketing Expense by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre Pharmaceuticals | $14.14M-40.6% | $23.82M+55.4% | $15.33M+0.9% | $15.19M+40.2% | $10.84M-35.7% | |
| Gyre | $0— | —— | —— | —— | $0— | |
| Research And Development Expense Excluding Acquired In Process Cost by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre Pharmaceuticals | $5.47M+37.0% | $3.99M+86.0% | $2.15M-35.7% | $3.34M+10.2% | $3.03M-15.5% | |
| Gyre | $1.27M+54.4% | $824K+280% | $217K+147% | $88K+33.3% | $66K-48.0% | |
| General And Administrative Expense by Business | ||||||
| All Other Segments | $6K+100% | $3K-72.7% | $11K+450% | $2K-33.3% | $3K— | |
| Gyre | $2.46M+11.1% | $2.21M+29.1% | $1.71M-13.0% | $1.97M+41.1% | $1.4M-3.6% | |
| Gyre Pharmaceuticals | $4.76M+6.0% | $4.49M+72.9% | $2.6M-9.2% | $2.86M-19.7% | $3.56M-11.5% | |
| Segment Expenditure Addition To Long Lived Assets by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre Pharmaceuticals | $178K+23.6% | $144K-78.4% | $668K+161% | $256K+110% | $122K— | |
| Gyre | $0— | —— | —— | —— | $0— | |
| Allocated Share Based Compensation Expense by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre | $870K+6.7% | $815K+0.9% | $808K+45.1% | $557K+29.8% | $429K-24.3% | |
| Gyre Pharmaceuticals | $1.71M-54.7% | $3.78M+1,016% | $339K-2.9% | $349K+347% | $78K— | |
| Fair Value Adjustment Of Warrants by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre | -$89K+66.2% | -$263K-1,243% | $23K+111% | -$212K+90.6% | -$2.26M-1,062% | |
| Gyre Pharmaceuticals | $0— | —— | —— | —— | $0— | |
| Revenue (Gross) by Product | ||||||
| Contiva | $849-100.0% | $2.5M+100% | $1.25M-30.0% | $1.78M+637,434% | $279— | |
| Etorel | $672-100.0% | $1.48M-4.2% | $1.54M— | —— | —— | |
| Other Product | $31— | —— | $81K— | —— | $73-100.0% | |
| Concentration Risk % by Product | ||||||
| Contiva | 3.8%+2.9pp | 0.9%-3.2pp | 4.1%-1.5pp | 5.6%+4.3pp | 1.3%— | |
| Etorel | 3%— | —— | 5.1%-0.9pp | 6%— | 0%— | |
| Other Product | 0.1%— | —— | 0.2%— | —— | 0.3%— | |
| Square Meter Area For Laboratory Center Under Lease by Geography | ||||||
| Nanjing | 700.0% | 700.0% | 700.0% | 700.0% | 70— | |
| Shanghai | 2240.0% | 2240.0% | 2240.0% | 2240.0% | 224— | |
| Zhengzhou | 1800.0% | 1800.0% | 1800.0% | 1800.0% | 180— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Gyre Therapeutics, Inc. break its business down?
- Gyre Therapeutics, Inc. (GYRE) reports revenue by business across 3 parts — All Other Segments, Gyre Pharmaceuticals and Gyre. Each is extracted from the segment footnotes and tracked over time.
- Where does Gyre Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gyre Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
